The Endocrine Society, a leading global organization representing thousands of physicians and scientists specializing in hormone research and clinical care, formally announced its support today for the introduction of the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act in the U.S. House of Representatives. This bipartisan legislative effort, spearheaded by a coalition of lawmakers including Representatives Diana DeGette (D-CO), Mariannette Miller-Meeks (R-IA), Kim Schrier (D-WA), Rob Bresnahan (R-PA), and Angie Craig (D-MN), seeks to dismantle the financial barriers that prevent millions of Americans from accessing the insulin they require to survive. By addressing the skyrocketing out-of-pocket costs associated with the drug and fostering a more competitive market for biosimilars, the bill aims to stabilize a healthcare crisis that has forced nearly 1.3 million Americans to ration their medication annually.
The introduction of the INSULIN Act represents a critical juncture in the long-standing debate over drug pricing in the United States. While recent federal actions, such as the Inflation Reduction Act, successfully implemented a $35 monthly cap on insulin for seniors enrolled in Medicare, a significant portion of the population—those with private insurance and the uninsured—remains vulnerable to high costs. The new House bill is designed to close these gaps, ensuring that the financial relief seen in the public sector is mirrored in the private commercial market.
Core Provisions of the INSULIN Act
The INSULIN Act is built upon three primary pillars intended to provide immediate relief and long-term market stability. The most prominent feature of the legislation is the establishment of a $35 monthly cap on out-of-pocket costs for insulin products for individuals covered by private, commercial insurance plans. This provision mirrors the successful cap currently in place for Medicare beneficiaries, aiming to standardize the cost of the drug regardless of a patient’s insurance provider.
Beyond the price cap, the legislation acknowledges the plight of the uninsured, who often face the highest "sticker prices" at the pharmacy counter. To address this, the bill mandates the creation of a dedicated resource center and a national hotline. This infrastructure is designed to connect uninsured patients with existing patient assistance programs, state-level subsidies, and other resources to ensure that no individual is left without access to insulin due to a lack of coverage.
Furthermore, the INSULIN Act seeks to address the systemic causes of high drug prices by promoting the development and market entry of biosimilar insulin products. Biosimilars are highly similar versions of original biological medications, much like generic versions of chemically synthesized drugs. By streamlining the pathway for these products to enter the market and encouraging competition, the bill intends to exert downward pressure on the list prices set by major pharmaceutical manufacturers.
The Endocrine Society’s Endorsement and Medical Perspective
The Endocrine Society’s endorsement of the bill is rooted in years of clinical observation and advocacy. Robert W. Lash, MD, the Society’s Chief Medical Officer, emphasized the moral and medical urgency of the legislation. "For the millions of Americans who rely on insulin every day, no one should have to choose between paying for their medication and meeting other basic needs," Dr. Lash stated. He further noted that the bipartisan nature of the bill is a vital step toward ensuring that "all people who need insulin can obtain it and stay healthy."
The Society’s support is not merely reactionary but is aligned with its formal "Insulin Access and Affordability Position Statement." This document, developed by experts in the field of endocrinology, has long advocated for a $35 monthly co-pay limit. The Society argues that when patients cannot afford insulin, the resulting complications—including diabetic ketoacidosis (DKA), kidney failure, blindness, and limb amputations—create a much higher financial and human cost for the U.S. healthcare system than the cost of the medication itself.
The Human and Economic Toll of Insulin Rationing
The necessity of the INSULIN Act is underscored by alarming data regarding diabetes prevalence and medication adherence in the United States. According to the Centers for Disease Control and Prevention (CDC), approximately 38.4 million Americans, or 11.6% of the total population, are living with diabetes. Of these, roughly 8.4 million rely on insulin to manage their blood sugar levels.
The financial burden of this reliance is staggering. A study published in the Annals of Internal Medicine highlighted that in 2021, nearly 20% of American adults with diabetes—approximately 1.3 million people—engaged in insulin rationing. Rationing behaviors include skipping doses, taking less than the prescribed amount, or delaying the purchase of a refill to save money. For those with Type 1 diabetes, for whom insulin is a physiological necessity, even a few days of rationing can be fatal.
From an economic perspective, the list price of insulin in the United States has historically been significantly higher than in other developed nations. While the cost to manufacture a vial of human insulin is estimated to be less than $5, and a vial of analog insulin less than $10, retail prices in the U.S. have frequently exceeded $300 per vial over the last decade. This disparity has been attributed to a complex "rebate" system involving Pharmacy Benefit Managers (PBMs) and manufacturers, which the INSULIN Act’s biosimilar provisions aim to disrupt.
Chronology of Legislative Action on Insulin
The journey toward the INSULIN Act has been marked by several years of incremental progress and political negotiation. The timeline below illustrates the evolution of insulin reform in the U.S. Congress:
- 2019–2020: Congressional hearings began to focus heavily on the rising cost of insulin, with executives from the "Big Three" manufacturers (Eli Lilly, Novo Nordisk, and Sanofi) testifying before committees regarding their pricing structures.
- 2021: The House passed the "Elijah E. Cummings Lower Drug Costs Now Act," which included provisions for insulin pricing, though the bill stalled in the Senate.
- August 2022: The Inflation Reduction Act (IRA) was signed into law. While it successfully capped insulin at $35 for Medicare Part D beneficiaries, a similar cap for the private market was stripped from the bill due to Senate parliamentarian rulings regarding the reconciliation process.
- Early 2023: In response to public and political pressure, the three major insulin manufacturers announced voluntary programs to cap out-of-pocket costs at $35 for many patients. However, advocates noted that these voluntary programs are not permanent and can be difficult for patients to navigate.
- Current Session: Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME) introduced a companion version of the INSULIN Act in the Senate. The introduction of the House version by Reps. DeGette, Miller-Meeks, and others creates a unified, bipartisan push across both chambers of Congress.
Analysis of Potential Implications and Market Impact
The passage of the INSULIN Act would signal a paradigm shift in how the U.S. handles essential, lifesaving medications. By codifying the $35 cap into law for private insurance, the bill provides a level of permanence and predictability that voluntary manufacturer programs lack. This stability is crucial for patients who must plan their monthly household budgets around their medical needs.
Furthermore, the emphasis on biosimilars could transform the insulin market. Currently, the market is dominated by three companies that control approximately 90% of the global supply. By facilitating the entry of new competitors, the INSULIN Act could lead to a "genericization" effect, where the presence of multiple interchangeable products drives down the base price of the drug. This would benefit not only the patients but also the employers and insurers who currently shoulder the high costs of these medications.
However, some analysts point out that while the $35 cap is a massive win for patients, it does not directly lower the "list price" of the drug paid by insurance companies. There is ongoing debate regarding whether the legislation should also include more aggressive "PBM reform" to address the "middlemen" who profit from high list prices through rebates. Nevertheless, the INSULIN Act is widely viewed as the most viable bipartisan path forward in the current political climate.
Broad Stakeholder Reactions
While the Endocrine Society has been a vocal proponent, other stakeholders have also weighed in on the legislation. Patient advocacy groups, such as JDRF (formerly the Juvenile Diabetes Research Foundation) and the American Diabetes Association (ADA), have long campaigned for such a cap, arguing that insulin is a public good rather than a luxury item.
On the other hand, pharmaceutical industry trade groups, such as PhRMA, have historically expressed concerns that price caps could stifle innovation. However, given that insulin is a century-old discovery—originally sold for $1 by its discoverers to ensure it would remain affordable—the "innovation" argument carries less weight with the public and lawmakers than it might for newer, experimental therapies.
The bipartisan nature of the House bill is particularly noteworthy. With sponsors ranging from progressive Democrats to conservative Republicans, the bill reflects a growing consensus that the "insulin crisis" is a matter of public health rather than partisan ideology. This cross-aisle support significantly increases the likelihood of the bill’s passage in a divided Congress.
Conclusion and Future Outlook
The introduction of the INSULIN Act in the House of Representatives marks a definitive step toward ending the era of insulin rationing in America. By combining immediate financial relief through price caps with long-term market reforms through biosimilar competition, the bill offers a comprehensive solution to a multifaceted problem.
The Endocrine Society has pledged to continue its work with both the House and the Senate to ensure the legislation moves through the committee process and reaches the President’s desk. For the millions of Americans living with diabetes, the stakes could not be higher. As the legislative process unfolds, the medical community and patient advocates alike remain focused on a singular goal: ensuring that no American is forced to risk their life because they cannot afford the medicine that keeps them alive. The INSULIN Act represents the most significant opportunity in a generation to make that goal a reality.
